دورية أكاديمية
أعرض في EDS

Genetically predicted hypothyroidism, thyroid hormone treatment, and the risk of cardiovascular diseases: a mendelian randomization study.

التفاصيل البيبلوغرافية
العنوان: Genetically predicted hypothyroidism, thyroid hormone treatment, and the risk of cardiovascular diseases: a mendelian randomization study.
المؤلفون: Zhang S; Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, People's Republic of China., Yu H; Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, People's Republic of China., Zhao Y; Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, People's Republic of China., Gong A; Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, People's Republic of China., Guan C; Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, People's Republic of China., Chen S; Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, People's Republic of China., Xiao B; Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, People's Republic of China., Lu J; Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, People's Republic of China. ljchb2h@hebmu.edu.cn.
المصدر: BMC cardiovascular disorders [BMC Cardiovasc Disord] 2024 Sep 10; Vol. 24 (1), pp. 479. Date of Electronic Publication: 2024 Sep 10.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100968539 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2261 (Electronic) Linking ISSN: 14712261 NLM ISO Abbreviation: BMC Cardiovasc Disord Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2001-
مواضيع طبية MeSH: Mendelian Randomization Analysis* , Hypothyroidism*/diagnosis , Hypothyroidism*/genetics , Hypothyroidism*/epidemiology , Thyroxine*/therapeutic use , Cardiovascular Diseases*/genetics , Cardiovascular Diseases*/epidemiology , Cardiovascular Diseases*/diagnosis , Genome-Wide Association Study* , Genetic Predisposition to Disease*, Humans ; Risk Assessment ; Hormone Replacement Therapy/adverse effects ; Risk Factors ; Phenotype ; Female ; Myocardial Infarction/genetics ; Myocardial Infarction/epidemiology ; Myocardial Infarction/diagnosis ; Polymorphism, Single Nucleotide ; Heart Failure/genetics ; Heart Failure/diagnosis ; Heart Failure/epidemiology ; Male ; Pharmacogenomic Variants ; Heart Disease Risk Factors
مستخلص: Background: In this study, we explored the impact of hypothyroidism and thyroid hormone replacement therapy on the risk of developing cardiovascular diseases, including myocardial infarction, heart failure, and cardiac death, via Mendelian randomization analysis.
Methods: Genetic instrumental variables related to hypothyroidism, levothyroxine treatment (refer to Participants were taking the medication levothyroxine sodium) and adverse cardiovascular events were obtained from a large publicly available genome-wide association study. Two-sample Mendelian randomization analysis was performed via inverse-variance weighting as the primary method. To ensure the reliability of our findings, we performed MR‒Egger regression, Cochran's Q statistic, and leave-one-out analysis. Additionally, multivariable Mendelian randomization was employed to regulate confounding factors, including systolic blood pressure (SBP), diastolic blood pressure (DBP), body mass index (BMI), diabetes, cholesterol, low-density lipoprotein (LDL), triglycerides and metformin. A mediation analysis was conducted to assess the mediating effects on the association between exposure and outcome by treating atrial fibrillation and stroke as mediator variables of levothyroxine treatment and bradycardia as mediator variables of hypothyroidism.
Results: Genetically predicted hypothyroidism and levothyroxine treatment were significantly associated with the risk of experiencing myocardial infarction [levothyroxine: odds ratio (OR) 3.75, 95% confidence interval (CI): 1.80-7.80; hypothyroidism: OR: 15.11, 95% CI: 2.93-77.88]. Levothyroxine treatment was also significantly related to the risk of experiencing heart failure (OR: 2.16, 95% CI: 1.21-3.88). However, no associations were detected between hypothyroidism and the risk of experiencing heart failure or between hypothyroidism or levothyroxine treatment and the risk of experiencing cardiac death. After adjusting for confounding factors, the results remained stable. Additionally, mediation analysis indicated that atrial fibrillation and stroke may serve as potential mediators in the relationships between levothyroxine treatment and the risk of experiencing heart failure or myocardial infarction.
Conclusion: The results of our study suggest a positive association between hypothyroidism and myocardial infarction and highlight the potential effects of levothyroxine treatment, the main thyroid hormone replacement therapy approach, on increasing the risk of experiencing myocardial infarction and heart failure.
(© 2024. The Author(s).)
References: Int J Epidemiol. 2003 Feb;32(1):1-22. (PMID: 12689998)
Curr Probl Cardiol. 2024 Feb;49(2):102204. (PMID: 37967804)
Annu Rev Psychol. 2007;58:593-614. (PMID: 16968208)
Crit Care Nurs Clin North Am. 2019 Mar;31(1):49-64. (PMID: 30736935)
Stat Med. 2016 May 20;35(11):1880-906. (PMID: 26661904)
Nat Genet. 2021 Aug;53(8):1260-1269. (PMID: 34226706)
Ann Intern Med. 2015 Aug 18;163(4):245-53. (PMID: 26121190)
Ann Endocrinol (Paris). 2014 Sep;75(4):220-6. (PMID: 25145560)
Front Endocrinol (Lausanne). 2022 Jul 14;13:913749. (PMID: 35909574)
Eur J Endocrinol. 2019 Jun 1;180(6):407-416. (PMID: 31035256)
Nat Commun. 2018 Jul 27;9(1):2941. (PMID: 30054458)
Genet Epidemiol. 2016 May;40(4):304-14. (PMID: 27061298)
Theranostics. 2022 Mar 6;12(6):2722-2740. (PMID: 35401820)
Front Endocrinol (Lausanne). 2024 Jan 08;14:1287463. (PMID: 38260160)
Adv Ther. 2019 Sep;36(Suppl 2):30-46. (PMID: 31485977)
Biomolecules. 2018 Sep 18;8(3):. (PMID: 30231508)
Eur Heart J. 2013 Jul;34(28):2159-219. (PMID: 23771844)
Diabetes Care. 2015 Sep;38(9):1657-64. (PMID: 26070591)
BMJ. 2018 Jul 12;362:k601. (PMID: 30002074)
BMC Med. 2017 Feb 2;15(1):21. (PMID: 28148249)
Eur J Endocrinol. 2010 Feb;162(2):289-94. (PMID: 19903797)
Med Clin North Am. 2012 Mar;96(2):269-81. (PMID: 22443975)
Nucleic Acids Res. 2024 Jan 5;52(D1):D871-D881. (PMID: 37941154)
Lancet. 2020 Mar 7;395(10226):795-808. (PMID: 31492503)
Sci Rep. 2024 Feb 28;14(1):4906. (PMID: 38418472)
Medicina (Kaunas). 2020 Apr 28;56(5):. (PMID: 32353935)
Thyroid. 2004;14 Suppl 1:S1-3. (PMID: 15142371)
Eur Heart J. 2021 Mar 1;42(9):919-933. (PMID: 33532862)
Cold Spring Harb Perspect Med. 2021 Feb 1;11(2):. (PMID: 32341063)
Eur J Epidemiol. 2015 Jul;30(7):543-52. (PMID: 25773750)
PLoS Genet. 2014 May 15;10(5):e1004383. (PMID: 24830394)
Curr Cardiol Rev. 2023;19(1):e280422204209. (PMID: 35657286)
Cardiovasc Res. 2023 Jan 18;118(17):3272-3287. (PMID: 35150240)
Am J Cardiol. 2017 Dec 1;120(11):1974-1979. (PMID: 28941600)
J Clin Endocrinol Metab. 2007 Jul;92(7):2415-20. (PMID: 17440013)
Nat Genet. 2018 May;50(5):693-698. (PMID: 29686387)
Horm Metab Res. 2015 Jul;47(8):577-80. (PMID: 25671800)
Int J Epidemiol. 2015 Apr;44(2):512-25. (PMID: 26050253)
J Clin Endocrinol Metab. 2014 Jan;99(1):E143-8. (PMID: 24203069)
J Thromb Haemost. 2011 Sep;9(9):1816-24. (PMID: 21729238)
Nat Genet. 2021 Oct;53(10):1415-1424. (PMID: 34594039)
J Clin Endocrinol Metab. 2021 Sep 27;106(10):e3890-e3900. (PMID: 34137866)
Endocr Rev. 2019 Jun 1;40(3):789-824. (PMID: 30649221)
PLoS Med. 2020 Mar 23;17(3):e1003062. (PMID: 32203549)
Endocrine. 2022 Mar;75(3):672-683. (PMID: 35032315)
JAMA Netw Open. 2022 May 2;5(5):e2211863. (PMID: 35552725)
Adv Ther. 2019 Sep;36(Suppl 2):47-58. (PMID: 31485975)
Nat Commun. 2020 Jan 9;11(1):163. (PMID: 31919418)
Nat Genet. 2018 Oct;50(10):1412-1425. (PMID: 30224653)
J Clin Endocrinol Metab. 2019 May 1;104(5):1725-1734. (PMID: 30517746)
Medicine (Baltimore). 2015 Jul;94(30):e1159. (PMID: 26222845)
Acta Med Scand. 1987;222(5):429-32. (PMID: 3425395)
Circ Res. 2003 Jan 10;92(1):81-7. (PMID: 12522124)
Endocrine. 2022 Feb;75(2):360-376. (PMID: 34713389)
Int J Endocrinol Metab. 2017 Mar 09;15(2):e42649. (PMID: 29026409)
Clin Appl Thromb Hemost. 2018 Oct;24(7):1014-1019. (PMID: 29742907)
Front Endocrinol (Lausanne). 2020 Apr 16;11:191. (PMID: 32425881)
Front Neurol. 2022 Apr 25;13:876165. (PMID: 35547384)
JAMA Cardiol. 2018 Apr 1;3(4):280-287. (PMID: 29490333)
J Clin Endocrinol Metab. 2022 May 17;107(6):e2572-e2580. (PMID: 35134201)
فهرسة مساهمة: Keywords: Heart failure; Hypothyroidism; Levothyroxine; Mendelian randomization; Myocardial infarction
المشرفين على المادة: Q51BO43MG4 (Thyroxine)
تواريخ الأحداث: Date Created: 20240910 Date Completed: 20240911 Latest Revision: 20240914
رمز التحديث: 20240914
مُعرف محوري في PubMed: PMC11386095
DOI: 10.1186/s12872-024-04132-2
PMID: 39256710
قاعدة البيانات: MEDLINE
الوصف
تدمد:1471-2261
DOI:10.1186/s12872-024-04132-2